secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-04-18T23:59:59+00:00
Accession:  0001437749-25-012337
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed appoints EVP Clinical Development and EVP Regulatory; COO Cobuzzi to depart July 1, 2025
--------------------------------------------------------------------------------

- Kelly Blackburn promoted to EVP Clinical Development (previously SVP), effective April 16, 2025; base salary $448,360, target bonus 35%.
- Mark De Rosch appointed EVP Regulatory and Government Affairs and Program Management, effective May 1, 2025; base salary $465,000, target bonus 35%.
- Robert Cobuzzi, COO, to depart July 1, 2025; not standing for re-election; receives lump-sum $479,723 plus pro-rated bonus and COBRA.
- Agreements include severance, non-compete, non-solicitation, and change-of-control provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/0001437749-25-012337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925012337/crvo20250417_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-012337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer